Lion Street Advisors LLC Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 1st, 2023

Lion Street Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 23.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,674 shares of the company’s stock after selling 1,699 shares during the quarter. Johnson & Johnson accounts for approximately 0.5% of Lion Street Advisors LLC’s holdings, making the stock its 24th biggest holding. Lion Street Advisors LLC’s holdings in Johnson & Johnson were worth $924,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Western Financial Corp CA bought a new position in Johnson & Johnson in the 4th quarter worth about $971,000. Gilman Hill Asset Management LLC lifted its position in Johnson & Johnson by 25.7% during the fourth quarter. Gilman Hill Asset Management LLC now owns 14,824 shares of the company’s stock valued at $2,619,000 after acquiring an additional 3,030 shares during the last quarter. Nvest Financial LLC raised its holdings in shares of Johnson & Johnson by 1.9% in the fourth quarter. Nvest Financial LLC now owns 18,555 shares of the company’s stock worth $3,278,000 after buying an additional 338 shares during the last quarter. Hengehold Capital Management LLC increased its stake in shares of Johnson & Johnson by 12.4% in the fourth quarter. Hengehold Capital Management LLC now owns 18,719 shares of the company’s stock worth $3,307,000 after acquiring an additional 2,066 shares during the period. Finally, Delta Investment Management LLC grew its position in Johnson & Johnson by 3.1% during the fourth quarter. Delta Investment Management LLC now owns 9,231 shares of the company’s stock valued at $1,631,000 after buying an additional 278 shares during the period. 67.94% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.0 %

NYSE JNJ opened at $155.00 on Friday. The stock has a market capitalization of $403.66 billion, a PE ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The firm has a 50 day moving average of $158.02 and a two-hundred day moving average of $167.12.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. The company’s revenue was down 4.4% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Insider Activity at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.35% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on JNJ. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday. They issued a “neutral” rating and a $164.00 target price on the stock. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Atlantic Securities boosted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Piper Sandler dropped their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $173.67.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.